Literature DB >> 16030290

Clinical studies with transdermal rotigotine in early Parkinson's disease.

W Poewe1, F Luessi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16030290     DOI： 10.1212/wnl.65.2_suppl_1.s11

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  [Report from NeuroUpdate in Wiesbaden (13/14 February 2009)].

Authors:  M Dieterich; G F Hamann
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

Review 2.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson's Disease.

Authors:  Makito Hirano; Chiharu Isono; Hikaru Sakamoto; Shuichi Ueno; Susumu Kusunoki; Yusaku Nakamura
Journal:  Dysphagia       Date:  2015-05-13       Impact factor: 3.438

4.  Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.

Authors:  J Kehr; X-J Hu; M Goiny; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2007-04-16       Impact factor: 3.575

5.  Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.

Authors:  Marina Braun; Willi Cawello; Hilmar Boekens; Rolf Horstmann
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

6.  The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Authors:  Dieter Scheller; Christoph Ullmer; Reinhard Berkels; Mirella Gwarek; Hermann Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-14       Impact factor: 3.000

7.  Current approaches to the treatment of Parkinson's disease.

Authors:  Joseph Jankovic; L Giselle Aguilar
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

8.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.